TGFB1 and melanoma: Interestingly, the m6A-C2 phenotype is associated with activation of the TGF-β signaling pathway and intermediate immune cell infiltration, and thus, we hypothesized that melanoma patients with m6A-C2 phenotype would benefit from the combination of immune checkpoint inhibitors and TGF-β blockers.